A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES)

Phase 1

• Conditions: Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]; Hypereosinophilic Syndrome (HES); MedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disorders

• Registration Number: EUCTR2019-002039-27-DE
• Lead Sponsor: AstraZeneca AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-05
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Provision of the signed and dated written informed consent of the
patient or the patient's legally authorised representative, and informed
assent from the patient (per local regulations) prior to any mandatory
study-specific procedures, sampling, and analyses
2. Males and females 12 years of age and older at the time of signing the
ICF
3. Documented diagnosis of HES (history of persistent eosinophilia
>1500 cells/µL without
secondary cause on 2 examinations [interval =1 month; Valent et al
2012] and evidence of end organ manifestations attributable to the
eosinophilia)
4. Documented negative testing for the FIP1L1-PDGFRA fusion tyrosine
kinase gene translocation
5. Stable HES treatment dose(s) and regimen for for =4 weeks at the
time of Visit 1
6. Signs or symptoms of HES worsening/flare and/or laboratory
abnormalities indicative of HES worsening/flare (other than isolated
eosinophilia) at Visit 1 or a documented history of 2 or more HES
worsening/flares within 12 months prior to Visit 1 requiring an
escalation in therapy.
-At least one flare within the past 12 months must not be related to a
decrease in HES therapy during the 4 weeks prior to the flare.
7. AEC =1000 cells/µL at Visit 1 (assessed by local laboratory)
8. Corticosteroid responsiveness defined as an AEC <1000 cells/µL after
a 2-day course of OCS (prednisone/prednisolone) 1 mg/kg/day at Visit
2 (assessed by local laboratory). Other OCSs in equivalent doses are
permitted.
9. WOCBP must agree to use a highly
effective method of birth control (confirmed by the Investigator) from
enrolment, throughout the study duration, and within 12 weeks after
last dose of IP and have a negative urine dipstick pregnancy test result
on Visit 1
10. Women not of childbearing potential are defined as women who are
either permanently sterilised (hysterectomy, bilateral oophorectomy, or
bilateral salpingectomy) or who are postmenopausal. Women will be
considered postmenopausal if they have been amenorrhoeic for =12
months prior to the planned date of enrolment without an alternative
medical cause
Are the trial subjects under 18? yes
Number of subjects for this age range: 6
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 108
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

1. Life-threatening HES and/or HES complication(s) as judged by the
Investigator:
(a) Medical intervention for HES-related life-threatening event(s) within
12 weeks prior to randomization, (b) History of thrombotic
complications, stroke, or significant cardiac damage related to HES, if
the respective events were life threatening and currently represent a
risk of life-threatening disease complications. Events that occurred in
the past but considered resolved or stable, can be accepted if, as per
Investigator's judgment participation in the study will not put the
patient at risk c) Disease severity that, in the opinion of the Investigator,
makes the patient inappropriate for inclusion in the study
2. Presence of FIP1L1-PDGFRA fusion tyrosine kinase gene translocation
or other known imatinib-sensitive mutation
3. Definitive diagnosis of eosinophilic granulomatosis with polyangiitis
4. Known, preexisting, clinically significant endocrine, autoimmune,
metabolic, neurological, renal, gastrointestinal, hepatic, haematological,
respiratory, or any other system abnormalities that are not associated
with HES and are uncontrolled with standard treatment which, in the
opinion of the Investigator, may put the patient at risk because of
his/her participation in the study, or may influence the results of the
study, or the patient's ability to complete the entire duration of the study
5.Hypereosinophilia of unknown significance
6. Cardiovascular: Documented history of any clinically significant
cardiac damage, clinically significant echocardiography (if available) or
ECG findings within 12 months prior to Visit 1 or clinically significant ECG
findings at screening that, in the opinion of the Investigator, may put the
patients at risk.
7. Known currently active liver disease
(a) Chronic stable hepatitis B and C (including positive testing for
hepatitis B surface antigen or hepatitis C antibody) or other stable
chronic liver disease are acceptable if patient otherwise meets eligibility
criteria. Stable chronic liver disease should generally be defined by the
absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia,
oesophageal or gastric varices, or persistent jaundice, or cirrhosis
(b) ALT or AST level =3× ULN during the screening period
(AST or ALT >5×ULN if documented HES with liver manifestations).
Transient increase of AST/ALT level that resolves by the time of
randomisation is acceptable if, in the Investigator's opinion, the patient
does not have an active liver disease and meets other eligibility criteria
8.Current or history of malignancy within 5 years before the screening
visit with the following exceptions:
(a) Patients treated for in situ carcinoma of the cervix who have
completed curative therapy and are in remission for at least 12 months
prior to signing the informed consent and
(b) Patients with basal cell or superficial squamous skin cancer.
(c) Patients who have had other malignancies are eligible provided that
the patient is in remission and curative therapy was completed at least 5
years prior to the date informed consent was obtained.
9. Diagnosis of systemic mastocytosis
10. Chronic or ongoing active infections requiring systemic treatment, as
well as clinically significant viral, bacterial, or fungal infection within 4
weeks prior to Visit 1
11. A helminth parasitic infection diagnosed within 24 weeks prior to
Visit 1 that has not been treated or has failed to respond to standard of
care therapy. A confirmation of a comp

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified